Advertisement

Topics

Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA

12:46 EDT 19 Oct 2016 | Biotech-Finances

Wednesday, October 19th 2016 at 11:20am UTC STOCKHOLM, Sweden–(BUSINESS WIRE)– Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (STO: SOBI) has been granted orphan designation by the European Commission (EC) for the company’s development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). SOBI003 will be included …

Cet article Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan
Designation for the Treatment of MPS IIIA
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA

NEXT ARTICLE

More From BioPortfolio on "Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA"

Quick Search
Advertisement
 

Relevant Topic

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...